Mitochondrial diseases can be caused by mutations of nuclear or mitochondrial DNA.^[@bibr1-2329048X19847377],[@bibr2-2329048X19847377]^ The multiple mitochondrial dysfunctions syndrome (MMDS) is a group of mitochondrial disorders caused by nuclear gene defects. They are inherited in an autosomal recessive manner. Six MMDSs have been described so far. These include MMDS1, which is caused by the *NFU1* gene defect (OMIM \#605711); MMDS2, which is caused by the *BOLA3* gene defect (OMIM \#614299); MMDS3 due to the *IBA57* gene defect (OMIM \#615330); MMDS4 due to the *ISCA2* gene defect (OMIM \#616370); MMDS5 due to the *ISCA1* gene defect (OMIM \#617613); and MMDS6 due to the *PMPCB* gene defect (OMIM \#617954).^[@bibr3-2329048X19847377][@bibr4-2329048X19847377][@bibr5-2329048X19847377][@bibr6-2329048X19847377][@bibr7-2329048X19847377][@bibr8-2329048X19847377]-[@bibr9-2329048X19847377]^

Multiple mitochondrial dysfunctions syndrome 4 (MMDS4; *ISCA2* gene defect; OMIM \#616370) is one of the MMDS. The MMDS4 shares most of the clinical and biochemical features and has a defect in the same metabolic pathway as the other types. This review will discuss the history of the knowledge of the *ISCA2* gene defect, its pathophysiology, clinical phenotypes, diagnostic approach, and future implications.

History {#section1-2329048X19847377}
=======

Multiple mitochondrial dysfunctions syndrome 4 was first described by Al-Hassnan et al in 2015 reporting 6 patients from 5 unrelated consanguineous families. In 2015, Alazami et al also described a single patient from a large cohort of consanguineous families in which 33 recessive novel genes were identified, not previously associated with any diseases. Subsequently, in 2017, Alfadhel et al reported 10 new patients with similar phenotypes. Other researchers have described 3 more patients with overlapping phenotypes.^[@bibr7-2329048X19847377],[@bibr8-2329048X19847377],[@bibr10-2329048X19847377][@bibr11-2329048X19847377]-[@bibr12-2329048X19847377]^

Pathophysiology {#section2-2329048X19847377}
===============

The mitochondrial iron--sulfur clusters pathway is essential for the biosynthesis of *iron--sulfur*-containing proteins in the mitochondria, cytosol, endoplasmic reticulum, and nucleus.^[@bibr13-2329048X19847377][@bibr14-2329048X19847377]-[@bibr15-2329048X19847377]^ In eukaryotes, iron--sulfur clusters are found in 2 forms: rhombic \[2Fe-2S\], and cubane \[4Fe-4S\].^[@bibr16-2329048X19847377]^ The proteins ISCA1, ISCA2, and IBA57 carry out the maturation of all cellular \[4Fe-4S\] clusters and carry them to their apoproteins either directly or through other specific proteins, such as NFU1, NUBPL, and BOLA3, which contribute to the maturation of specific \[4Fe-4S\]-containing proteins.^[@bibr17-2329048X19847377]^ One of the biochemical abnormalities of ISCA2 gene defects that has been observed is hyperglycinemia. This occurs due to defects in the iron--sulfur clusters pathway that leads to the inhibition of lipoic acid synthase that is vital for the glycine cleavage system, an impairment of which results in hyperglycinemia. Lipoic acid is a vital cofactor for 5 redox reactions in humans: 2 enzymes are essential for energy production (α-ketoglutarate dehydrogenase, pyruvate dehydrogenase, and 3 contribute to amino acid pathways \[branched-chain ketoacid dehydrogenase, BCKDH\], 2-oxoadipate dehydrogenase, and the glycine cleavage system).^[@bibr18-2329048X19847377]^

Functionally, the ISCA2, ISCA1, and the IBA57 proteins are involved in the assembly of a mitochondrial iron--sulfur cluster \[4Fe-4S\], which is important for electron transfer and mitochondrial function.^[@bibr17-2329048X19847377]^ There is a strong interaction between the ISCA1 and the ISCA2 proteins, yet the functional significance of this interaction is still unknown. The ISCA1 is required for the maturation of mitochondrial Fe4S4 proteins in mature skeletal muscle, whereas ISCA2 and IBA57 are not required in the 2 postmitotic cell types, under standard physiological conditions.^[@bibr19-2329048X19847377]^

Using in vivo studies, specific interactions of the ISCA1 and ISCA2 with different proteins such as IBA57, GLRX5, and NFU1 of the late mitochondrial machinery have been described. However, there is a strong interaction observed between the ISCA2 and the IBA57, while neither IBA57 nor ISCA2 knockdown causes Fe-S metabolism phenotypes.^[@bibr19-2329048X19847377]^ Interestingly, mutations in the IBA57 and ISCA2 in humans cause disorders in early age, suggesting association with development processes.^[@bibr6-2329048X19847377]^ Using the {2Fe-2S} cluster, IBA57 forms a heterodimeric complex with the ISCA2, which is essential for the formation of the complex.^[@bibr20-2329048X19847377]^

Furthermore, ISCA1 strongly interacts with the NFU1, suggesting its association with the ISCA1 in Fe4S4 assembly. Previously, NFU1 has been reported to cause MMDS with respiratory complex, suggesting mitochondrial Fe4S4 biogenesis.^[@bibr5-2329048X19847377],[@bibr21-2329048X19847377]^

Clinical Phenotypes {#section3-2329048X19847377}
===================

[Table 1](#table1-2329048X19847377){ref-type="table"} summarizes the clinical features of *ISCA2* gene defects. To date, 20 cases have been reported from 18 different families: 13 females and 7 males. All cases, except for 1 Italian family, are from Saudi Arabia. Typically, the patients have had normal antenatal and birth histories and attain normal development initially, before showing rapid deterioration between the ages of 2 and 7 months with a triad of neurodevelopmental regression, optic atrophy with nystagmus, and diffuse white matter disease. Spasticity and axial hypotonia present in 95% (n = 19) and 65% (n = 13) of probands, respectively. Typically, by the age of 1 to 2, the patients are in a vegetative state; this can continue for years. During that period, the probands are prone to recurrent chest infections that can require ventilator support. Most cases reported died during early childhood.^[@bibr7-2329048X19847377],[@bibr8-2329048X19847377],[@bibr10-2329048X19847377][@bibr11-2329048X19847377]-[@bibr12-2329048X19847377],[@bibr22-2329048X19847377]^

###### 

Clinical Characteristics of Patients With an *ISCA2* Gene Defect.

![](10.1177_2329048X19847377-table1)

                                                                 Al-Hassnan et al, 2015         Alazami et al, 2015                                        Alfadhel et al, 2017   Alaimo et al, 2018   Toldo et al, 2018   Total, %
  -------------------------------------------------------------- ------------------------------ ---------------------------------------------------------- ---------------------- -------------------- ------------------- --------------------
  No. of patients                                                6                              1                                                          10                     2                    1                   20
  No. of families                                                5                              1                                                          9                      2                    1                   18
  Female:male ratio                                              4:2                            1:0                                                        6:4                    1:1                  1:0                 13:7
  No. of siblings or relatives who died of a similar condition   5                              5                                                          5                      8                    0                   23
  Origin                                                         Saudi                          Saudi                                                      Saudi                  Saudi                Italy               Saudi; 19/20 (95%)
  Age at onset (months)                                          3-7                            NA                                                         3-7                    3 and 6              2                   
  Common clinical features                                                                                                                                                                                                 
   Neurodevelopmental regression                                 6/6                            1/1                                                        10/10                  2/2                  1/1                 20/20 (100%)
   Global developmental delay                                    6/6                            1/1                                                        10/10                  2/2                  1/1                 20/20 (100%)
   Spasticity                                                    6/6                            NA                                                         10/10                  2/2                  1/1                 19/20 (95%)
   Optic atrophy                                                 6/6                            NA                                                         10/10                  2/2                  0/1                 18/20 (90%)
   Nystagmus                                                     NA                             NA                                                         10/10                  2/2                  1/1                 13/20 (65%)
   Axial hypotonia                                               NA                             NA                                                         10/10                  2/2                  1/1                 13/20 (65%)
   Seizure                                                       NA                             NA                                                         3/10                   0/2                  0/1                 3/20 (15%)
   Mortality rate                                                4/6                            1/1                                                        5/10                   1/2                  1/1                 12/20 (60%)
  MRI and MRS findings                                                                                                                                                                                                     
   Diffuse bilateral cerebral WM                                 6/6                            1/1                                                        10/10                  2/2                  1/1                 20/20 (100%)
   Cerebellar WM                                                 3/6                            NA                                                         9/10                   2/2                  1/1                 15/20 (75%)
   Spinal cord                                                   1/6                            NA                                                         7/10                   2/2                  1/1                 11/20 (55%)
  Molecular genetics findings                                                                                                                                                                                              
  Type of mutation                                               Homozygous missense mutation   Compound heterozygous mutation                                                                                             
   *ISCA2* gene defect                                           c.229G\>A (p.Gly77Ser)         \[(c.295delT (p.Phe99Leufs\*18); c.334A\>G (p.Ser112Gly)                                                                   

Abbreviations: MRI, magnetic resonance imaging; MRS, MR spectroscopy; NA, not available; WM, white matter.

Seizures have been reported in 15% (n = 3) of cases reported in the literature. Two patients have generalized tonic--clonic seizures while the third one had focal seizures.^[@bibr8-2329048X19847377]^ Other manifestations reported include relative macrocephaly, joint laxity, short fourth metacarpals, and cutaneous toe syndactyly.^[@bibr11-2329048X19847377]^

Neuroradiological Findings {#section4-2329048X19847377}
==========================

Magnetic resonance imaging scans of the brain were carried out in all the patients and showed diffuse bilateral white matter involvement. Cerebellar white matter abnormalities were presented in 75% (n = 15) of the patients, and the spinal cord was affected in 55% (n = 11). In general, no structural abnormalities were observed, with signal abnormalities being predominant. Magnetic resonance spectroscopy, which to our knowledge was done in 13 (65%) patients, showed elevated glycine peaks in 2 (10%) cases and elevated lactate peaks in 5 (25%) cases.

Biochemical Abnormalities {#section5-2329048X19847377}
=========================

Elevated lactate is a vital marker in the diagnosis of individuals with a suspected mitochondrial disease. To our knowledge, cerebrospinal fluid glycine was tested in only 3 of the 20 patients and was observed to be increased in all 3 (100%) patients. Plasma glycine was tested in 13 of 20 patients and was observed to be increased in 3 (23%) patients.^[@bibr8-2329048X19847377],[@bibr10-2329048X19847377],[@bibr11-2329048X19847377]^ Therefore, both (glycine elevation on cerebrospinal fluid and plasma glycine) could be tested in other patients as potential biomarkers.

Other biochemical investigations, such as tests for ammonia, acylcarnitine profile and screening urine for organic acids, were unremarkable. Respiratory chain enzymology was checked in 2 (10%) patients and both showed complex II and IV deficiency. Muscle biopsies were done in a few patients, and revealed mild histopathological abnormalities, including myofiber size variation and atrophic changes. The mitochondria were observed to be shortened, and the outlines were stretched out and angulated. There was severe mitochondrial depletion in the fibroblasts of the patients.^[@bibr7-2329048X19847377]^ However, myopathic features such as fiber hypertrophy or degeneration were absent, and there were no ragged red fibers.^[@bibr7-2329048X19847377],[@bibr11-2329048X19847377]^

Genetics {#section6-2329048X19847377}
========

The *ISCA2* gene is located at chromosome 14q24.3. The *ISCA2* gene has 4 exons, 154 amino acids, and a molecular mass of 16 476 Da. It encodes an A-type iron--sulfur cluster protein in mitochondria. This protein is essential in the maturation of mitochondrial iron--sulfur proteins. Two transcript variants encoding different isoforms have been found for this gene. Two mutations have been detected in 18 different families: one is a homozygous missense mutation (c.229G\>A; p.Gly77Ser) which is a founder mutation in Saudi families, and a compound heterozygous mutation \[(c.295delT; p.Phe99Leufs\*18); (c.334A\>G; p.Ser112Gly)\] in 1 Italian family. An autosomal recessive inheritance pattern is suggested by the consanguinity reported in most cases. Therefore, the recurrence risk is 25% (n = 5) in each pregnancy. There is no clear genotype--phenotype correlation.

Diagnosis {#section7-2329048X19847377}
=========

Diagnosis can be established by DNA molecular genetic testing of the *ISCA2* gene.

Treatment {#section8-2329048X19847377}
=========

To date, no curative treatment has been discovered, and disease management is exclusively supportive. The management of *ISCA2* gene defects requires a multidisciplinary team approach including pediatricians, neurologists, geneticists, genetic counselors, dieticians, physiotherapists, and occupational therapists. Patients are at risk of gastroesophageal incoordination and swallowing difficulties which can lead to aspiration, malnutrition, and failure to thrive. In many patients, a feeding tube, such as gastrostomy tube, would be an efficient solution to ensure the patient receives sufficient calories and avoids recurrent aspirations. Additionally, periodic vision assessments are essential to have a clear knowledge about severity and progressive behavior of optic atrophy. Finally, regular follow-up visits with physiotherapists and occupational therapists are mandatory.

Prognosis {#section9-2329048X19847377}
=========

Multiple mitochondrial dysfunctions syndrome 4 as a result of the *ISCA2* gene defect is an apparently lethal disease and carries a poor prognosis. Of the cases known, 60% died early in childhood. The remainder had severe global developmental delay. The assumption of the lethality of this disease is limited by the small sample size (of 20 cases).

Conclusion {#section10-2329048X19847377}
==========

Clinicians should consider *ISCA2* gene defects as a diagnosis for any patient with the triad of neurodevelopmental regression, optic atrophy with nystagmus, and diffuse white matter disease. Additional case series will increase our knowledge of the severe clinical presentation, complications, and proper management of the disease.
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